Tylosin is an antibiotic of the macrolide group. It is active against most gram-positive and some gram-negative microorganisms, including Staphylococcus spp., Streptococcus spp., Escherichia coli, Pasteurella spp., Haemophilus spp., Leptospira spp., Erysipelothrix rhusiopathiae, Corynebacteriu, spp., Chlamydia spp., Treponema spp.
The mechanism of action of tylosin is based on the suppression of bacterial protein synthesis by binding of the active substance to the 50S ribosomal subunit.
When administered orally, tylosin is well absorbed from the gastrointestinal tract and creates therapeutic concentrations of tylosin in the blood and tissues of the animal's body.
The veterinary product is excreted from the body mainly in the bile and in smaller quantities in the urine.
The veterinary product, according to the degree of exposure belongs to low-hazard substances (hazard class 4 according to GOST 12.1.007-76).